  6 ADVERSE REACTIONS

  EXCERPT:   Most common adverse reactions (incidence >= 5%) are acne, application site reaction, abnormal lab tests, and prostatic disorders. (  6.1  )  To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or      www.fda.gov/medwatch  .  

 

  6.1 Clinical Trial Experience

  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

       Clinical Trials in Hypogonadal Men    

   Table 1  shows the incidence of all adverse events judged by the investigator to be at least possibly related to treatment with AndroGel 1% and reported by >1% of patients in a 180 Day, Phase 3 study.

 Table 1: Adverse Events Possibly, Probably or Definitely Related to Use of AndroGel 1% in the 180-Day Controlled Clinical Trial 
  * Lab≠B-NonOSE_AE   test≠I-NonOSE_AE   abnormal≠I-NonOSE_AE  occurred in nine patients with one or more of the following events reported:  elevated≠B-OSE_Labeled_AE  hemoglobin or  hematocrit≠I-OSE_Labeled_AE ,  hyperlipidemia≠B-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   triglycerides≠I-OSE_Labeled_AE ,  hypokalemia≠B-OSE_Labeled_AE ,  decreased≠B-OSE_Labeled_AE   HDL≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   glucose≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   creatinine≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   total≠I-OSE_Labeled_AE   bilirubin≠I-OSE_Labeled_AE .    
  ** Prostate≠B-OSE_Labeled_AE   disorders≠I-OSE_Labeled_AE  included five patients with  enlarged≠B-OSE_Labeled_AE   prostate≠I-OSE_Labeled_AE , one with  BPH≠B-OSE_Labeled_AE , and one with  elevated≠B-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE  results.    
  *** Testis≠B-OSE_Labeled_AE   disorders≠I-OSE_Labeled_AE  were reported in two patients: one with  left≠B-OSE_Labeled_AE   varicocele≠I-OSE_Labeled_AE  and one with slight  sensitivity≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   left≠I-OSE_Labeled_AE   testis≠I-OSE_Labeled_AE .    
  
   Adverse Event                               Dose of AndroGel 1%     
   50 mg                                       75 mg              100 mg               
                                               N = 77             N = 40                N = 78               
  Acne≠B-OSE_Labeled_AE                                         1%                 3%                    8%                     
  Alopecia≠B-OSE_Labeled_AE                                     1%                 0%                    1%                     
  Application≠B-OSE_Labeled_AE   Site≠I-OSE_Labeled_AE   Reaction≠I-OSE_Labeled_AE                    5%                 3%                    4%                     
  Asthenia≠B-OSE_Labeled_AE                                     0%                 3%                    1%                     
  Depression≠B-OSE_Labeled_AE                                   1%                 0%                    1%                     
  Emotional≠B-OSE_Labeled_AE   Lability≠I-OSE_Labeled_AE                           0%                 3%                    3%                     
  Gynecomastia≠B-OSE_Labeled_AE                                 1%                 0%                    3%                     
  Headache≠B-OSE_Labeled_AE                                     4%                 3%                    0%                     
  Hypertension≠B-OSE_Labeled_AE                                 3%                 0%                    3%                     
  Lab≠B-NonOSE_AE   Test≠I-NonOSE_AE   Abnormal≠I-NonOSE_AE *                          6%                 5%                    3%                     
  Libido≠B-OSE_Labeled_AE   Decreased≠I-OSE_Labeled_AE                             0%                 3%                    1%                     
  Nervousness≠B-OSE_Labeled_AE                                  0%                 3%                    1%                     
  Pain≠B-OSE_Labeled_AE   Breast≠I-OSE_Labeled_AE                                  1%                 3%                    1%                     
  Prostate≠B-OSE_Labeled_AE   Disorder≠I-OSE_Labeled_AE  *≠I-OSE_Labeled_AE  *≠I-OSE_Labeled_AE                          3%                 3%                    5%                     
  Testis≠B-OSE_Labeled_AE   Disorder≠I-OSE_Labeled_AE ***                          3%                 0%                    0%                     
          Other less common adverse reactions, reported in fewer than 1% of patients included:  amnesia≠B-OSE_Labeled_AE ,  anxiety≠B-OSE_Labeled_AE ,  discolored≠B-OSE_Labeled_AE   hair≠I-OSE_Labeled_AE ,  dizziness≠B-OSE_Labeled_AE ,  dry≠B-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE ,  hirsutism≠B-OSE_Labeled_AE ,  hostility≠B-OSE_Labeled_AE ,  impaired≠B-OSE_Labeled_AE   urination≠I-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ,  penis≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE ,  peripheral≠B-OSE_Labeled_AE   edema≠I-OSE_Labeled_AE ,  sweating≠B-OSE_Labeled_AE , and  vasodilation≠B-OSE_Labeled_AE .
 

 In this 180 day clinical trial,  skin≠B-OSE_Labeled_AE   reactions≠I-OSE_Labeled_AE   at≠I-OSE_Labeled_AE   the≠I-OSE_Labeled_AE   site≠I-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   application≠I-OSE_Labeled_AE  were reported with AndroGel 1%, but none was severe enough to require treatment or discontinuation of drug.

 Six patients (4%) in this trial had adverse events that led to discontinuation of AndroGel 1%. These events included:  cerebral≠B-NonOSE_AE   hemorrhage≠I-NonOSE_AE ,  convulsion≠B-NonOSE_AE  (neither of which were considered related to AndroGel 1% administration),  depression≠B-OSE_Labeled_AE ,  sadness≠B-OSE_Labeled_AE ,  memory≠B-OSE_Labeled_AE   loss≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   prostate≠I-OSE_Labeled_AE   specific≠I-OSE_Labeled_AE   antigen≠I-OSE_Labeled_AE , and  hypertension≠B-OSE_Labeled_AE . No AndroGel 1% patient discontinued due to  skin≠B-NonOSE_AE   reactions≠I-NonOSE_AE .

 In a separate uncontrolled pharmacokinetic study of 10 patients, two had adverse events associated with AndroGel 1%; these were  asthenia≠B-OSE_Labeled_AE  and  depression≠B-OSE_Labeled_AE  in one patient and  increased≠B-OSE_Labeled_AE   libido≠I-OSE_Labeled_AE  and  hyperkinesia≠B-OSE_Labeled_AE  in the other.

 In a 3 year, flexible dose, extension study, the incidence of all adverse events judged by the investigator to be at least possibly related to treatment with AndroGel 1% and reported by > 1% of patients is shown in  Table 2  .

 Table 2: Adverse Events Possibly, Probably or Definitely Related to Use of AndroGel 1% in the 3 Year, Flexible Dose, Extension Study 
   Adverse Event                                           Percent of Subjects                           
                                                         (N = 162)                                       
  
  + Lab≠B-NonOSE_AE   test≠I-NonOSE_AE   abnormal≠I-NonOSE_AE  occurred in 15 patients with one or more of the following events reported:  elevated≠B-OSE_Labeled_AE   AST≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   ALT≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   testosterone≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE  hemoglobin or  hematocrit≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   cholesterol≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   cholesterol≠I-OSE_Labeled_AE  /≠I-OSE_Labeled_AE  LDL≠I-OSE_Labeled_AE   ratio≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   triglycerides≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   HDL≠I-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   serum≠I-OSE_Labeled_AE   creatinine≠I-OSE_Labeled_AE .    
  * Urinary≠B-OSE_Labeled_AE   symptoms≠I-OSE_Labeled_AE  included  nocturia≠B-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   hesitancy≠I-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   incontinence≠I-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   retention≠I-OSE_Labeled_AE ,  urinary≠B-OSE_Labeled_AE   urgency≠I-OSE_Labeled_AE  and  weak≠B-OSE_Labeled_AE   urinary≠I-OSE_Labeled_AE   stream≠I-OSE_Labeled_AE .    
  ** Testis≠B-OSE_Labeled_AE   disorders≠I-OSE_Labeled_AE  included three patients. There were two with a  non≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  palpable≠I-OSE_Labeled_AE   testis≠I-OSE_Labeled_AE  and one with slight  right≠B-OSE_Labeled_AE   testicular≠I-OSE_Labeled_AE   tenderness≠I-OSE_Labeled_AE .    
  
  Lab≠B-NonOSE_AE   Test≠I-NonOSE_AE   Abnormal≠I-NonOSE_AE +                                      9.3                                             
  Skin≠B-OSE_Labeled_AE   dry≠I-OSE_Labeled_AE                                                 1.9                                             
  Application≠B-OSE_Labeled_AE   Site≠I-OSE_Labeled_AE   Reaction≠I-OSE_Labeled_AE                                5.6                                             
  Acne≠B-OSE_Labeled_AE                                                     3.1                                             
  Pruritus≠B-OSE_Labeled_AE                                                 1.9                                             
  Enlarged≠B-OSE_Labeled_AE   Prostate≠I-OSE_Labeled_AE                                        11.7                                            
  Carcinoma≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   Prostate≠I-OSE_Labeled_AE                                    1.2                                             
  Urinary≠B-OSE_Labeled_AE   Symptoms≠I-OSE_Labeled_AE *                                       3.7                                             
  Testis≠B-OSE_Labeled_AE   Disorder≠I-OSE_Labeled_AE **                                       1.9                                             
  Gynecomastia≠B-OSE_Labeled_AE                                             2.5                                             
  Anemia≠B-OSE_Labeled_AE                                                   2.5                                             
        Two patients reported serious adverse events considered possibly related to treatment:  deep≠B-OSE_Labeled_AE   vein≠I-OSE_Labeled_AE   thrombosis≠I-OSE_Labeled_AE   (≠I-OSE_Labeled_AE  DVT≠I-OSE_Labeled_AE ) and  prostate≠B-OSE_Labeled_AE   disorder≠I-OSE_Labeled_AE  requiring a transurethral resection of the prostate (TURP).
 

 Discontinuation for adverse events in this study included: two patients with  application≠B-OSE_Labeled_AE   site≠I-OSE_Labeled_AE   reactions≠I-OSE_Labeled_AE , one with  kidney≠B-OSE_Labeled_AE   failure≠I-OSE_Labeled_AE , and five with  prostate≠B-OSE_Labeled_AE   disorders≠I-OSE_Labeled_AE  (including  increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   serum≠I-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE  in 4 patients, and  increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE  with  prostate≠B-OSE_Labeled_AE   enlargement≠I-OSE_Labeled_AE  in a fifth patient).

       Increases in Serum PSA Observed in Clinical Trials of Hypogonadal Men    

 During the initial 6-month study, the mean change in  PSA≠B-OSE_Labeled_AE   values≠I-OSE_Labeled_AE  had a statistically significant  increase≠I-OSE_Labeled_AE  of 0.26 ng/mL. Serum PSA was measured every 6 months thereafter in the 162  hypogonadal≠B-Not_AE_Candidate  men on AndroGel 1% in the 3-year extension study. There was no additional statistically significant  increase≠B-NonOSE_AE  observed in mean  PSA≠I-NonOSE_AE  from 6 months through 36 months. However, there were  increases≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   serum≠I-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE  observed in approximately 18% of individual patients. The overall mean change from baseline in serum PSA values for the entire group from month 6 to 36 was 0.11 ng/mL.

 Twenty-nine patients (18%) met the per-protocol criterion for  increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   serum≠I-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE , defined as >2X the baseline or any single serum  PSA≠B-OSE_Labeled_AE   >≠I-OSE_Labeled_AE  6≠I-OSE_Labeled_AE   ng≠I-OSE_Labeled_AE  /≠I-OSE_Labeled_AE  mL≠I-OSE_Labeled_AE . Most of these (25/29) met this criterion by at least  doubling≠B-OSE_Labeled_AE   of≠I-OSE_Labeled_AE   their≠I-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE  from baseline. In most cases where  PSA≠B-OSE_Labeled_AE   at≠I-OSE_Labeled_AE   least≠I-OSE_Labeled_AE   doubled≠I-OSE_Labeled_AE  (22/25), the maximum serum PSA value was still <2 ng/mL. The first occurrence of a pre-specified, post-baseline  increase≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   serum≠I-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE  was seen at or prior to Month 12 in most of the patients who met this criterion (23 of 29; 79%).

 Four patients met this criterion by having a serum  PSA≠B-OSE_Labeled_AE   >≠I-OSE_Labeled_AE  6≠I-OSE_Labeled_AE   ng≠I-OSE_Labeled_AE  /≠I-OSE_Labeled_AE  mL≠I-OSE_Labeled_AE  and in these, maximum serum PSA values were 6.2 ng/mL, 6.6 ng/mL, 6.7 ng/mL, and 10.7 ng/mL. In two of these patients,  prostate≠B-OSE_Labeled_AE   cancer≠I-OSE_Labeled_AE  was detected on biopsy. The first patient's PSA levels were 4.7 ng/mL and 6.2 ng/mL at baseline and at Month 6/Final, respectively. The second patient's PSA levels were 4.2 ng/mL, 5.2 ng/mL, 5.8 ng/mL, and 6.6 ng/mL at baseline, Month 6, Month 12, and Final, respectively.

   6.2 Postmarketing Experience

  The following adverse reactions have been identified during post approval use of AndroGel 1%. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure (Table 3).

     Table 3: Adverse Drug Reactions from Postmarketing Experience of AndroGel 1% by MedDRA System Organ Class 
  Blood≠B-NonOSE_AE   and≠I-NonOSE_AE   the≠I-NonOSE_AE   lymphatic≠I-NonOSE_AE   system≠I-NonOSE_AE   disorders≠I-NonOSE_AE :           Elevated≠B-OSE_Labeled_AE   Hgb≠I-OSE_Labeled_AE , Hct ( polycythemia≠B-OSE_Labeled_AE )                     
  Cardiovascular≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                           Myocardial≠B-OSE_Labeled_AE   infarction≠I-OSE_Labeled_AE ,  stroke≠B-OSE_Labeled_AE                         
  Endocrine≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                                Hirsutism≠B-OSE_Labeled_AE                                             
  Gastrointestinal≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                         Nausea≠B-OSE_Labeled_AE                                                
  General≠B-NonOSE_AE   disorders≠I-NonOSE_AE   and≠I-NonOSE_AE   administration≠I-NonOSE_AE   site≠I-NonOSE_AE   reactions≠I-NonOSE_AE :   Asthenia≠B-OSE_Labeled_AE ,  edema≠B-OSE_Labeled_AE ,  malaise≠B-OSE_Labeled_AE                              
  Genitourinary≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                            Impaired≠B-OSE_Labeled_AE   urination≠I-OSE_Labeled_AE                                    
  Hepatobiliary≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                            Abnormal≠B-OSE_Labeled_AE   liver≠I-OSE_Labeled_AE   function≠I-OSE_Labeled_AE   tests≠I-OSE_Labeled_AE  (e.g. transaminases,  elevated≠B-OSE_Labeled_AE  GGTP,  bilirubin≠I-OSE_Labeled_AE )   
  Investigations≠B-NonOSE_AE :                                     Elevated≠B-OSE_Labeled_AE   PSA≠I-OSE_Labeled_AE ,  electrolyte≠B-OSE_Labeled_AE   changes≠I-OSE_Labeled_AE  (nitrogen, calcium, potassium, phosphorus, sodium),  changes≠B-OSE_Labeled_AE   in≠I-OSE_Labeled_AE   serum≠I-OSE_Labeled_AE   lipids≠I-OSE_Labeled_AE  ( hyperlipidemia≠B-OSE_Labeled_AE ,  elevated≠B-OSE_Labeled_AE   triglycerides≠I-OSE_Labeled_AE ,  decreased≠B-OSE_Labeled_AE   HDL≠I-OSE_Labeled_AE ),  impaired≠B-OSE_Labeled_AE   glucose≠I-OSE_Labeled_AE   tolerance≠I-OSE_Labeled_AE ,  fluctuating≠B-OSE_Labeled_AE   testosterone≠I-OSE_Labeled_AE   concentrations≠I-OSE_Labeled_AE ,  weight≠B-OSE_Labeled_AE   increase≠I-OSE_Labeled_AE    
  Neoplasms≠B-NonOSE_AE   benign≠I-NonOSE_AE  ,≠I-NonOSE_AE   malignant≠I-NonOSE_AE   and≠I-NonOSE_AE   unspecified≠I-NonOSE_AE   (≠I-NonOSE_AE  cysts≠I-NonOSE_AE   and≠I-NonOSE_AE   polyps≠I-NonOSE_AE ):   Prostate≠B-OSE_Labeled_AE   cancer≠I-OSE_Labeled_AE                                       
  Nervous≠B-NonOSE_AE   system≠I-NonOSE_AE :                                     Headache≠B-OSE_Labeled_AE ,  dizziness≠B-OSE_Labeled_AE ,  sleep≠B-OSE_Labeled_AE   apnea≠I-OSE_Labeled_AE ,  insomnia≠B-OSE_Labeled_AE            
  Psychiatric≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                              Depression≠B-OSE_Labeled_AE ,  emotional≠B-OSE_Labeled_AE   lability≠I-OSE_Labeled_AE ,  decreased≠B-OSE_Labeled_AE   libido≠I-OSE_Labeled_AE ,  nervousness≠B-OSE_Labeled_AE ,  hostility≠B-OSE_Labeled_AE ,  amnesia≠B-OSE_Labeled_AE ,  anxiety≠B-OSE_Labeled_AE    
  Reproductive≠B-NonOSE_AE   system≠I-NonOSE_AE   and≠I-NonOSE_AE   breast≠I-NonOSE_AE   disorders≠I-NonOSE_AE :           Gynecomastia≠B-OSE_Labeled_AE ,  mastodynia≠B-OSE_Labeled_AE ,  prostatic≠B-OSE_Labeled_AE   enlargement≠I-OSE_Labeled_AE ,  testicular≠B-OSE_Labeled_AE   atrophy≠I-OSE_Labeled_AE ,  oligospermia≠B-OSE_Labeled_AE ,  priapism≠B-OSE_Labeled_AE  (frequent or  prolonged≠B-OSE_Labeled_AE   erections≠I-OSE_Labeled_AE )   
  Respiratory≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                              Dyspnea≠B-OSE_Labeled_AE                                               
  Skin≠B-NonOSE_AE   and≠I-NonOSE_AE   subcutaneous≠I-NonOSE_AE   tissue≠I-NonOSE_AE   disorders≠I-NonOSE_AE :             Acne≠B-OSE_Labeled_AE ,  alopecia≠B-OSE_Labeled_AE ,  application≠B-OSE_Labeled_AE   site≠I-OSE_Labeled_AE   reaction≠I-OSE_Labeled_AE  ( pruritus≠B-OSE_Labeled_AE ,  dry≠B-OSE_Labeled_AE   skin≠I-OSE_Labeled_AE ,  erythema≠B-OSE_Labeled_AE ,  rash≠B-OSE_Labeled_AE ,  discolored≠B-OSE_Labeled_AE   hair≠I-OSE_Labeled_AE ,  paresthesia≠B-OSE_Labeled_AE ),  sweating≠B-OSE_Labeled_AE    
  Vascular≠B-NonOSE_AE   disorders≠I-NonOSE_AE :                                 Hypertension≠B-OSE_Labeled_AE ,  vasodilation≠B-OSE_Labeled_AE  ( hot≠B-OSE_Labeled_AE   flushes≠I-OSE_Labeled_AE ),  venous≠B-OSE_Labeled_AE   thromboembolism≠I-OSE_Labeled_AE    
            Secondary Exposure to Testosterone in Children    Cases of  secondary≠B-OSE_Labeled_AE   exposure≠I-OSE_Labeled_AE  to testosterone resulting in virilization of  ch ildren≠B-OSE_Labeled_AE  ≠≠I-OSE_Labeled_AE  I≠I-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  OSE≠I-OSE_Labeled_AE _Labeled_AE  have been reported in postmarket surveillance. Signs and symptoms of these reported cases have included  enlargement≠B-NonOSE_AE   of≠I-NonOSE_AE   the≠I-NonOSE_AE   clitoris≠I-NonOSE_AE  (with surgical intervention) or the penis,  development≠B-NonOSE_AE   of≠I-NonOSE_AE   pubic≠I-NonOSE_AE   hair≠I-NonOSE_AE ,  increased≠B-NonOSE_AE   erections≠I-NonOSE_AE  and libido,  aggressive≠B-NonOSE_AE   behavior≠I-NonOSE_AE , and  advanced≠B-NonOSE_AE   bone≠I-NonOSE_AE   age≠I-NonOSE_AE . In most cases with a reported outcome, these signs and symptoms were reported to have regressed with removal of the testosterone gel exposure. In a few cases, however,  enlarged≠B-NonOSE_AE   genitalia≠I-NonOSE_AE  did not fully return to age appropriate normal size, and  bone≠B-NonOSE_AE   age≠I-NonOSE_AE   remained≠I-NonOSE_AE   modestly≠I-NonOSE_AE   greater≠I-NonOSE_AE   than≠I-NonOSE_AE   chronological≠I-NonOSE_AE   age≠I-NonOSE_AE . In some of the cases, direct contact with the sites of application on the skin of men using testosterone gel was reported. In at least one reported case, the reporter considered the possibility of secondary exposure from items such as the testosterone gel user's shirts and/or other fabric, such as towels and sheets  [see Warnings and Precautions (  5.2  )]  .

